EM
EMMA.US Emmaus Life Sciences Inc
- Market cap
- USD 1.05M
- P/E
- -
- P/B
- 35.48x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is EMMA.US undervalued?
Graham numberThe Graham number of Emmaus Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Emmaus Life Sciences Inc fundamental analysis
No fundamental analysis for Emmaus Life Sciences Inc yet.
Emmaus Life Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which include…
Full company profileEmmaus Life Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Emmaus Life Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 85.1K | 129K | 1.32M | 22.8M | 23.2M | 20.6M | 18.4M | 29.6M | 16.7M | 12.5M | 16.6M |
| Gross Profit | 79.6K | 75.0K | 488K | 21.7M | 20.9M | 17.3M | 15.8M | 28.3M | 15.5M | 11.6M | 15.6M |
| Operating Income | -3.77M | -7.10M | -10.2M | -4.51M | -43.0K | -6.13M | -6.59M | 3.54M | -1.89M | 231K | 5.94M |
| EBITDA | -4.02M | -7.05M | -10.1M | -27.2M | 17.0K | -8.04M | -6.53M | 3.62M | -910K | -310K | 3.52M |
| Net Income | -5.94M | -7.11M | -9.60M | -54.8M | 1.35M | -15.9M | -10.7M | -3.73M | -6.45M | -7.49M | -3.99M |
| EPS | -56 | -15 | -11 | -1.30 | 0.03 | -0.32 | -0.22 | -0.06 | -0.10 | -0.11 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 1.32M | 6.10M | 5.15M | 59.5M | 59.3M | 56.7M | 48.2M | 35.2M | 23.6M | 21.4M | 16.4M |
| Total Liabilities | 1.58M | 1.55M | 1.87M | 70.5M | 64.7M | 78.2M | 82.3M | 82.9M | 80.1M | 85.0M | 82.5M |
| Shareholders' Equity | -257K | 4.55M | 3.29M | -11.1M | -5.42M | -21.5M | -34.1M | -47.8M | -56.5M | -63.6M | -66.2M |
| Cash & Short-term Investments | 318K | 5.45M | 3.25M | 29.7M | 2.49M | 2.28M | 2.02M | 2.55M | 1.39M | 2.13M | 2.81M |
| Total Debt | 93.6K | 36.2K | 591K | 19.5M | 19.0M | 29.9M | 25.1M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.98M | -4.79M | -9.04M | -4.52M | -2.45M | -1.25M | -5.07M | -1.50M | -2.29M | -11.0K | 2.70M |
| Capital Expenditure | 82.3K | 130K | 55.2K | 60.0K | 26.2M | 73.0K | 26.0K | 17.0K | 12.0K | 1.00K | 0.00 |
| Free Cash Flow | -3.06M | -4.92M | -9.09M | -4.58M | -28.6M | -1.33M | -5.10M | -1.52M | -2.30M | -12.0K | 2.69M |
| Ratios | |||||||||||
| ROE | - | -156.4% | -292.1% | - | - | - | - | - | - | - | - |
| ROA | -450.0% | -116.7% | -186.3% | -92.2% | 2.3% | -28.1% | -22.2% | -10.6% | -27.3% | -35.0% | -24.4% |
| Net Profit Margin | -6,981.1% | -5,535.3% | -729.7% | -241.0% | 5.8% | -77.4% | -58.1% | -12.6% | -38.7% | -60.2% | -24.0% |
| Debt to Equity | - | 0.01x | 0.18x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Emmaus Life Sciences Inc dividends
Emmaus Life Sciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Jul 18, 2019.
Who owns Emmaus Life Sciences Inc
- Insiders 47.08%
- Institutions 0.00%
- Public & others 52.92%
- Shares outstanding 70.2M
- Free float 36.9M
Emmaus Life Sciences Inc company profile
- Company name
- Emmaus Life Sciences Inc
- Ticker
- EMMA.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 32
- Fiscal year end
- December
- Address
- 21250 Hawthorne Boulevard, Torrance, CA, United States, 90503
- Phone
- 310 214 0065
- Website
- emmausmedical.com
About Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Emmaus Life Sciences Inc management
5- Mr. Willis C. Lee M.S.CEO & Chairman of the Board · born 1960
- Ms. Hiroko Huynh CPAChief Accounting Officer · born 1980
- Dr. Charles W. Stark Pharm.D.Chief Science Officer and EVP of Clinical Development & Medical Affairs · born 1955
- Mr. Dale E. Short J.D.Legal Consultant & Corporate Secretary
- Mr. Kurt H. Kruger M.B.A., M.S.Consultant · born 1955